BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B

Bristol-Myers Squibb return on equity (ROE)

Bristol-Myers Squibb's return on equity is 39.48%: net income of 9.24B USD over the last twelve months on shareholders' equity of 23.40B USD.

Today
39.48%
Average, 5 years
14.02%
Low, 5 years
-54.69%
High, 5 years
41.55%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 9.24B ÷ 23.40B = 39.48%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Bristol-Myers Squibb's return on equity so high?

Net margin
14.6%
profit on each dollar of sales
Asset turnover
0.54×
sales on each dollar of assets
Equity multiplier
4.87×
assets on each dollar of equity
Return on equity
38.2%
FY2025
  • FY202514.6% × 0.54 × 4.87 = 38.2%
  • FY2024-18.5% × 0.52 × 5.67 = -54.8%
  • FY202317.8% × 0.47 × 3.23 = 27.3%
  • FY202213.7% × 0.48 × 3.12 = 20.4%
  • FY202115.1% × 0.42 × 3.04 = 19.5%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today39.48%9.24B23.40B
FY202531 Dec 202538.19%7.06B18.47B
FY202431 Dec 2024-54.69%-8.93B16.34B
FY202331 Dec 202327.32%8.04B29.43B
FY202231 Dec 202220.43%6.35B31.06B
FY202131 Dec 202119.51%7.01B35.95B
FY202031 Dec 2020-23.78%-9.00B37.82B
FY201931 Dec 20196.71%3.46B51.60B
FY201831 Dec 201835.26%4.95B14.03B
FY201731 Dec 20178.30%975.00M11.74B
FY201631 Dec 201627.86%4.51B16.18B
FY201531 Dec 201511.43%1.63B14.27B
FY201431 Dec 201413.66%2.03B14.85B
FY201331 Dec 201317.03%2.58B15.15B
FY201231 Dec 201218.36%2.50B13.62B
FY201131 Dec 201132.97%5.26B15.96B
FY201031 Dec 201028.72%4.51B15.71B
FY200931 Dec 200979.92%11.86B14.84B
FY200831 Dec 200851.00%6.24B12.24B
FY200731 Dec 200720.50%2.17B10.56B
FY200631 Dec 200615.86%1.59B9.99B
FY200531 Dec 200526.77%3.00B11.21B
FY200431 Dec 200423.41%2.39B10.20B
FY200331 Dec 200331.74%3.11B9.79B
FY200231 Dec 200224.41%2.14B8.76B
FY200131 Dec 200153.27%4.83B9.08B
FY200031 Dec 200051.32%4.71B9.18B
FY199931 Dec 199948.20%4.17B8.65B
FY199831 Dec 199841.46%3.14B7.58B
FY199731 Dec 199744.40%3.21B7.22B
FY199631 Dec 199643.38%2.85B6.57B
FY199531 Dec 199531.12%1.81B5.82B
FY199431 Dec 199432.29%1.84B5.70B
FY199331 Dec 199332.98%1.96B5.94B
FY199231 Dec 199226.63%1.60B6.02B
FY199131 Dec 199135.48%2.06B5.80B
FY199031 Dec 199032.26%1.75B5.42B
FY198931 Dec 198914.69%747.00M5.08B
FY198831 Dec 198825.34%1.25B4.95B
FY198731 Dec 198722.46%1.07B4.76B

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Bristol-Myers Squibb's ROE

Source: Financial Modeling PrepVerified against SEC filings